ACAD
48.81
0.00
N/A%
AEMD
9.99
0.00
N/A%
APRI
1.44
0.00
N/A%
ARNA
4.04
0.00
N/A%
ATEC
1.36
0.00
N/A%
CNAT
4.74
-0.08
-1.66%
CRXM
0.3
0.00
N/A%
CYTX
0.44
0.00
N/A%
DXCM
84.65
0.00
N/A%
GNMK
8.5
0.00
N/A%
HALO
23.34
+0.21
+0.91%
ILMN
219.3
0.00
N/A%
INNV
0.155
0.00
N/A%
INO
7.29
0.00
N/A%
ISCO
0.043
0.00
N/A%
ISIS
54.93
+1.76
+3.31%
LGND
108.26
+0.48
+0.45%
LPTN
0.27
0.00
N/A%
MBVX
2.16
0.00
N/A%
MEIP
1.56
0.00
N/A%
MNOV
3.75
0.00
N/A%
MRTX
28.61
0.00
N/A%
MSTX
0.447
0.00
N/A%
NBIX
50.12
+0.1
+0.20%
NUVA
55.01
0.00
N/A%
ONCS
6.06
0.00
N/A%
ONVO
3.38
+0.01
+0.30%
OREX
4
0.00
N/A%
OTIC
25.77
0.00
N/A%
QDEL
20.71
0.00
N/A%
RCPT
227.86
+0.38
+0.17%
RGLS
8.2
0.00
N/A%
RMD
57.95
0.00
N/A%
SCIE
0.018
0.00
N/A%
SPHS
0.87
0.00
N/A%
SRNE
20.78
0.00
N/A%
TROV
7.88
+0.07
+0.90%
VICL
0.644
0.00
N/A%
ZGNX
19.31
0.00
N/A%
ACAD
48.81
0.00
N/A%
AEMD
9.99
0.00
N/A%
APRI
1.44
0.00
N/A%
ARNA
4.04
0.00
N/A%
ATEC
1.36
0.00
N/A%
CNAT
4.74
-0.08
-1.66%
CRXM
0.3
0.00
N/A%
CYTX
0.44
0.00
N/A%
DXCM
84.65
0.00
N/A%
GNMK
8.5
0.00
N/A%
HALO
23.34
+0.21
+0.91%
ILMN
219.3
0.00
N/A%
INNV
0.155
0.00
N/A%
INO
7.29
0.00
N/A%
ISCO
0.043
0.00
N/A%
ISIS
54.93
+1.76
+3.31%
LGND
108.26
+0.48
+0.45%
LPTN
0.27
0.00
N/A%
MBVX
2.16
0.00
N/A%
MEIP
1.56
0.00
N/A%
MNOV
3.75
0.00
N/A%
MRTX
28.61
0.00
N/A%
MSTX
0.447
0.00
N/A%
NBIX
50.12
+0.1
+0.20%
NUVA
55.01
0.00
N/A%
ONCS
6.06
0.00
N/A%
ONVO
3.38
+0.01
+0.30%
OREX
4
0.00
N/A%
OTIC
25.77
0.00
N/A%
QDEL
20.71
0.00
N/A%
RCPT
227.86
+0.38
+0.17%
RGLS
8.2
0.00
N/A%
RMD
57.95
0.00
N/A%
SCIE
0.018
0.00
N/A%
SPHS
0.87
0.00
N/A%
SRNE
20.78
0.00
N/A%
TROV
7.88
+0.07
+0.90%
VICL
0.644
0.00
N/A%
ZGNX
19.31
0.00
N/A%
Home » Bio: Keith Murphy

Bio: Keith Murphy

Keith Murphy, chairman and chief executive officer, is a veteran of biotechnology startup Alkermes, Inc, where he played a central role on the development team for their first approved product, Nutropin (hGH) Depot. He moved to Amgen in 1997 and developed several other novel formulation and device products. He has more than 17 years of experience in biotechnology, including serving in product strategy and director of process development roles at Amgen. His 10 years at Amgen included four years as global operations leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. He holds a B.S. in chemical engineering from MIT and is an alumnus of the UCLA Anderson School of Management.